BioSpace News Archive

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the Company will present at the virtual LILRB/ILT Symposium: A Deep Dive into Myeloid Checkpoint Therapeutics in Cancer on Tuesday, April 26, 2022.

The Bloomberg New Economy International Cancer Coalition (the “Coalition”) today called for a permanent paradigm change in the way cancer patients are diagnosed, treated and cared for across the globe.

According to Report, the trauma implants market is estimated to expand growth at a CAGR of 6.9% from 2021 to 2031.

CS Genetics, a privately held genomics-technology company, announced the appointment of Chad Geringer as Vice President of Global Sales.

Having a sole spotlight on this market guarantees better nature of items, client faithfulness and a laid out conveyance network that can build the accessibility of the item across the globe.

The generic injectable is a pharmaceutical drug with the same active ingredient as the innovator drug and is equivalent to it in terms of route of administration, intended use, performance, strength, dosage, and side effects.

The swine flu vaccine is used to prevent the spread of H1N1 influenza that started as a pandemic in the year 2009.

The US Food and Drug Administration has recently approved a 2.0mg dose of Ozempic as an approved Type 2 diabetes treatment when given as a once-weekly injection.

Today, the U.S. Food and Drug Administration is warning the public of the risk of false results, inappropriate use and inappropriate interpretation of results with non-invasive prenatal screening (NIPS) tests, also called cell-free DNA tests or non-invasive prenatal tests (NIPT).

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report first quarter 2022 financial results after the close of the U.S. financial markets on Wednesday, May 4, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.